Decoding Cancer Plasticity for
Human-Relevant Drug Response.
Delivering early insights into treatment efficacy and resistance using next-generation functional assays with exceptional biological fidelity.
Delivering early insights into treatment efficacy and resistance using next-generation functional assays with exceptional biological fidelity.
Because preclinical models don’t predict human reality. Cymoplive bridges that gap with human-relevant tumor biology.
Late-stage failure is the most expensive mistake in drug development. Cymoplive reduces risk before it becomes loss.
Yet translation to human cancer remains unreliable. Cymoplive delivers predictive human tumor insight without dependence on animal models.
Oncology failure is not driven only by incorrect targets. It is driven by the ability of cancer to evolve under therapeutic pressure.
Most screening systems measure early response, but they do not assess how tumors adapt and develop resistance. These escape mechanisms often remain undetected until after extensive and costly animal studies, or even during clinical trials, while important development decisions are based on short-term data.
This gap increases risk, cost, and lost opportunity.


Cancer cells often do not simply die in response to therapy. Instead, they survive through adaptive, non-genetic changes that are difficult to detect in conventional models.
Cymoplive makes these dynamic cellular adaptations visible for the first time ever, enabling the identification of resistance mechanisms that typically remain undetected in early screening systems.
Our proprietary organ-like hydrogel engineered to recreate human-relevant physiological conditions and preserve tumour heterogeneity as observed in human cancers.

OncoTrix™ is a first-in-class platform that uses structured conditions to reveal functional adaptive behaviours of cancer cells missed by existing systems.

Live behavioural scoring that converts adaptive behaviour into actionable measures of cancer aggressiveness, drug efficacy pharmacodynamics, resistance/relapse risk, and combination performance.


Cymoplive is a proprietary platform that delivers time-resolved insights into tumor adaptive behaviour under controlled experimental conditions.
Our platform and analytical framework have been validated in human carcinoma models, including pancreatic, triple-negative breast, and cervical cancers, demonstrating robust and reproducible performance across indications.



Customizable organ-specific tumor microenvironments that deliver clinically relevant insights.
Run multiple experiments simultaneously, accelerating discovery with optimised resource utilisation.
Extract migration, toxicity, viability, and adaptation data from a single, precious sample — without splitting or repeating assays.
Capture comprehensive, multiparametric data from every experiment instead of relying on a single endpoint.
Precision pharmacodynamic insights that guide mechanism validation, dose optimisation, and clinical strategy.
















Gain early insight into resistance risk and make smarter pipeline decisions, in collaboration with Cymoplive.